Editorial High-Density Lipoprotein NO Failure in Heart Failure Ali Javaheri, Daniel J. Rader
D
espite numerous epidemiological studies demonstrating that high-density lipoprotein cholesterol (HDL-C) levels are inversely associated with cardiovascular risk,1–3 several lines of evidence now indicate that targeting HDL-C levels to reduce the risk of cardiovascular events is unlikely to be effective. Studies of pharmacological interventions to raise HDL-C, such as niacin4,5 and 2 cholesteryl ester transfer protein inhibitors,6,7 have shown no benefit in reducing cardiovascular events. In addition, data from a large Mendelian randomization study have shown that some genetic variants associated with HDL-C seem to have little relationship to coronary heart disease.8 As a result, there is currently skepticism about whether interventions specifically to raise HDL-C levels will decrease the risk of cardiovascular events.
Article, see p 1345 This failure of the so-called HDL cholesterol hypothesis has been accompanied by a shift toward a more rigorous, basic understanding of HDL as a molecule with multiple functions that can be differentiated from simple measures of HDL cholesterol mass. One of the important functions of HDL is its role in promoting cellular cholesterol efflux and reverse cholesterol transport. Our group and others have shown that the capacity of HDL to promote cholesterol efflux from macrophages ex vivo is inversely related to the risk of coronary heart disease even after controlling for HDL-C levels.9,10 Furthermore, niacin therapy does not augment cholesterol efflux despite raising HDL levels in statin-treated patients,11 which could explain the lack of efficacy of niacin despite increased HDL-C levels. Although more studies are certainly warranted, one hypothesis is that therapies that improve cholesterol efflux capacity and reverse cholesterol transport, such as infusion of a reconstituted HDL12 composed of apolipoprotein A1 and phospholipids, may improve cardiovascular outcomes. Beyond promoting cholesterol efflux, HDL is known to have anti-inflammatory,13 antioxidant,14 and nitric oxide (NO)–promoting functions.15 HDL particles have been shown to be dysfunctional in various disease states such as diabetes The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association. From the Division of Cardiology, Department of Medicine (A.J.) and Institute for Translational Medicine and Therapeutics, Cardiovascular Institute, and Department of Medicine (D.J.R.), University of Pennsylvania, Philadelphia. Correspondence to Daniel J. Rader, MD, 11th Floor, Smilow Center for Translational Research,3400 Civic Center Blvd, Bldg 421,Philadelphia, PA 19104-5158. E-mail [email protected] (Circ Res. 2013;113:1275-1277.) © 2013 American Heart Association, Inc. Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.113.302667
mellitus and psoriasis, with evidence of reduced protective functions of HDL potentially contributing to increased cardiovascular risk.16,17 In this issue of Circulation Research, Adams et al18 show that HDL is dysfunctional in congestive heart failure (CHF) specifically with respect to its ability to promote NO production from endothelial cells. They show that HDL from New York Heart Association Class II and III patients, compared with HDL from healthy subjects, has significantly reduced the ability to activate endothelial NO synthase (eNOS) and generate NO production. They suggest a mechanism linked to significantly reduced paraxonase-1 and increased HDL malondialdehyde, leading to increased stimulation of protein kinase C βII phosphorylation and altered phosphorylation of eNOS. Exercise training in subjects with CHF significantly improved the ability of HDL to promote NO biosynthesis. These studies extend previous work showing that HDL isolated from patients with coronary artery disease and acute coronary syndrome is defective in its ability to promote NO production.19 Although these findings are extremely provocative, this is a small, hypothesis-generating study with only 24 heart failure subjects and 16 healthy controls. It is surprising that although >80% of the controls were hypertensive, control subjects did not seem to benefit from exercise training to the same degree as patients with heart failure. Furthermore, although one might predict that patients with ischemic heart disease would be treated with statins compared with healthy controls, the low density lipoprotein (LDL) levels were not significantly lower between the heart failure subjects and controls at the beginning of the study. The authors do not comment on which patients in this study were treated with statins, which have been suggested to attenuate the proinflammatory effects of HDL.20 Finally, because heart failure often improves with medical therapy alone, the duration of time these patients were stable on optimal medical therapy is an important variable that could explain improvements seen in heart failure, independent of exercise training. The authors propose that the improvement in endothelial function after exercise training in patients with heart failure may be because of improvements in the quality of their HDL. To support this argument, the authors demonstrate a significant correlation between absolute change in endothelial function and HDL-induced NO production in patients with heart failure. A lack of improvement in endothelial function in the control group, which did not benefit from improved HDL function, would strengthen their argument. It is of course possible that exercise training improved both endothelial function and HDL function and that these 2 effects were independent. Could the improvements in LDL, which are known to negatively affect NO production,21 be responsible for the changes in endothelial function? Of note, LDL levels did decrease significantly with
Downloaded from http://circres.ahajournals.org/ at University of Exeter (exu) / England on March 18, 2015 1275
1276 Circulation Research December 6, 2013
Figure. Healthy high-density lipoprotein (HDL) and HDL containing sphingosine 1-phosphate (S1P) promote nitric oxide (NO) production through activation of scavenger receptor B1 (SR-BI) and S1PR3 receptor. Dysfunctional HDL rich in malondialdehyde (MDA) and symmetrical dimethylarginine (SDMA) decreases NO production via activation of lectin-like oxidized LDL receptor-1 (LOX-1) or Tolllike receptor-2 (TLR-2). eNOS indicates endothelial nitric oxide synthase; PI3K, phosphoinositide-3 kinase; and PKC-βII, protein kinase C βII.
exercise training. It is possible that in vivo, increased levels of lipid peroxidases seen by the authors correlate with higher levels of oxidized LDL that disrupt eNOS function.21 Exercise training itself is known to have positive effects on CHF, including reductions in all-cause mortality and heart failure hospitalization.22,23 What are the possible mechanisms by which exercise may benefit a patient with CHF? Possibilities include improvements in endothelial function, coronary perfusion, decreased peripheral vascular resistance, skeletal muscle remodeling, or increasing oxygen uptake and resistance to fatigue.24 In this study, a brief 12-week exercise training program improved peak oxygen consumption, one of the strongest predictors of mortality in CHF. If the benefit of exercise training in heart failure is significantly related to its ability to promote endothelial function, and HDL has the same effects, then improving HDL function in and of itself might be a reasonable target of therapy in heart failure. To understand whether HDL could be of therapeutic benefit in heart failure, a more detailed understanding of mechanism will be necessary. What are the molecular mechanisms that underlie the effects of exercise training on HDL-stimulated NO production in heart failure? The authors speculate that exercise training reduces overall oxidative load, as assayed by measuring plasma lipid peroxidases, causing a decrease in malondialdehyde binding to HDL. Because there was no effect of exercise training on paraxonase-1 activity or the HDL proteome, the authors eliminate these as possible molecular mechanisms. The authors discuss that HDL binding to scavenger receptor B1 may stimulate eNOS.25 One possibility is that malondialdehyde-rich HDL is less able to bind to scavenger receptor B1. Another intriguing, but unexplored, hypothesis is that changes in the HDL lipidome may be responsible for the enhanced NO production that occurs after exercise. The HDLassociated sphingolipid sphingosine 1-phosphate (S1P) binds
the S1P3 G-protein–coupled receptor to active phosphoinositide-3 kinase and Akt leading to eNOS activation.26 Animal models indicate that HDL/S1P may have numerous cardioprotective and vasculoprotective effects.27,28 However, in a mouse model of cardiomyopathy, S1P levels are actually increased because of downregulation of the cystic fibrosis transmembrane regulator, the major intracellular important mechanism for S1P.29 HDL-associated S1P may be decreased in patients with coronary artery disease,30 but changes in HDL/S1P levels have not been described in CHF or after chronic exercise training in humans. One may speculate that perhaps certain lipid-modified HDL, such as malondialdehyde-rich HDL, is not able to properly target S1P to its receptors on endothelial cells, resulting in decreased Akt activation and NO production. The authors leave unexplored the mechanisms by which dysfunctional HDL may stimulate protein kinase C βII, thereby inhibiting NO production. One possibility is that dysfunctional HDL signals through other receptors, such as lectin-like oxidized LDL receptor-1, to stimulate protein kinase C βII.19 Perhaps there are additional modifications of HDL in heart failure, such as increased symmetrical dimethylarginine, which are associated with further endothelial dysfunction via activation of Toll-like receptor-2.31 We propose a model whereby healthy HDL signals through scavenger receptor B1 and S1PR3 to induce NO production but speculate that dysfunctional HDL may cause decreased NO production via activation of lectin-like oxidized LDL receptor-1 or Toll-like receptor-2 (Figure). In summary, the findings of Adams et al18 further highlight that HDL function can be separated from HDL-C mass with regard to association with cardiovascular disease and relevant clinical end points. It remains tempting to speculate that interventions that improve HDL functional properties, such as cholesterol efflux capacity or NO promotion, would reduce
Downloaded from http://circres.ahajournals.org/ at University of Exeter (exu) / England on March 18, 2015
Javaheri and Rader Exercise Training Augments NO Production in CHF 1277 cardiovascular events. In fact, targeting NO in CHF patients with therapies such as hydralazine and nitrates provides cardiovascular outcome benefit in selected patients.32 Although it has not been tested in heart failure, reconstituted HDL is known to improve endothelial function in hypercholesterolemic men.33 In light of this report, it would be of substantial interest to determine whether reconstituted HDL can improve eNOS activity and NO production in patients with CHF. If so, it would then be appropriate to consider whether reconstituted HDL may improve outcomes in patients with CHF.
Disclosures Dr Rader receives personal consulting fees from Merck, Eli Lilly, and Vascular Strategies.
References 1. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15. 2. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988;8:737–741. 3. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis. 1988;8:207–211. 4. HPS2-THRIVE Collaborative Group. Hps2-thrive randomized placebocontrolled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279–1291 5. Boden WE, Probstfield JL, Anderson T, Chaitman BR, DesvignesNickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267 6. Schwartz GG, Olsson AG, Abt M, et al.; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099. 7. Barter PJ, Caulfield M, Eriksson M, et al.; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122. 8. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380:572–580. 9. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–135. 10. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, Hazen SL. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol. 2013;33:1696–1705. 11. Khera AV, Patel PJ, Reilly MP, Rader DJ. The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol. 2013;62:1909–1910. 12. Patel S, Drew BG, Nakhla S, Duffy SJ, Murphy AJ, Barter PJ, Rye KA, Chin-Dusting J, Hoang A, Sviridov D, Celermajer DS, Kingwell BA. Reconstituted high-density lipoprotein increases plasma highdensity lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol. 2009;53: 962–971. 13. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95:764–772. 14. Navab M, Yu R, Gharavi N, Huang W, Ezra N, Lotfizadeh A, Anantharamaiah GM, Alipour N, Van Lenten BJ, Reddy ST, Marelli D. High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr Atheroscler Rep. 2007;9:244–248.
15. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoproteininduced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 2003;278:9142–9149. 16. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol. 2010;30:151–155. 17. Mehta NN, Li R, Krishnamoorthy P, Yu Y, Farver W, Rodrigues A, Raper A, Wilcox M, Baer A, DerOhannesian S, Wolfe M, Reilly MP, Rader DJ, VanVoorhees A, Gelfand JM. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012;224:218–221. 18. Adams V, Besler C, Fischer T, et al. Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties. Circ Res. 2013;113:1345–1355. 19. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121:2693–2708. 20. Navab M, Anantharamaiah GM, Hama S, Hough G, Reddy ST, Frank JS, Garber DW, Handattu S, Fogelman AM. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2005;25:1426–1432. 21. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem. 1999;274:32512–32519. 22. O’Connor CM, Whellan DJ, Lee KL, et al.; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1439–1450. 23. Belardinelli R, Georgiou D, Cianci G, Purcaro A. 10-year exercise training in chronic heart failure: a randomized controlled trial. J Am Coll Cardiol. 2012;60:1521–1528. 24. Downing J, Balady GJ. The role of exercise training in heart failure. J Am Coll Cardiol. 2011;58:561–569. 25. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, Marcel YL, Anderson RG, Mendelsohn ME, Hobbs HH, Shaul PW. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001;7:853–857. 26. Nofer JR, van der Giet M, Tölle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004;113:569–581. 27. Theilmeier G, Schmidt C, Herrmann J, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation. 2006;114:1403–1409. 28. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of highdensity lipoprotein effects in cardiovascular protection. Cardiovasc Res. 2009;82:201–211. 29. Meissner A, Yang J, Kroetsch JT, Sauvé M, Dax H, Momen A, NoyanAshraf MH, Heximer S, Husain M, Lidington D, Bolz SS. Tumor necrosis factor-α-mediated downregulation of the cystic fibrosis transmembrane conductance regulator drives pathological sphingosine1-phosphate signaling in a mouse model of heart failure. Circulation. 2012;125:2739–2750. 30. Sattler KJ, Herrmann J, Yün S, Lehmann N, Wang Z, Heusch G, Sack S, Erbel R, Levkau B. High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention. Eur Heart J. 2009;30:1894–1902. 31. Speer T, Rohrer L, Blyszczuk P, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity. 2013;38:754–768. 32. Cole RT, Kalogeropoulos AP, Georgiopoulou VV, Gheorghiade M, Quyyumi A, Yancy C, Butler J. Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions. Circulation. 2011;123:2414–2422. 33. Spieker LE, Sudano I, Hürlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Lüscher TF, Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399–1402.
Downloaded from http://circres.ahajournals.org/ at University of Exeter (exu) / England on March 18, 2015
High-Density Lipoprotein: NO Failure in Heart Failure Ali Javaheri and Daniel J. Rader Circ Res. 2013;113:1275-1277 doi: 10.1161/CIRCRESAHA.113.302667 Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Copyright © 2013 American Heart Association, Inc. All rights reserved. Print ISSN: 0009-7330. Online ISSN: 1524-4571
The online version of this article, along with updated information and services, is located on the World Wide Web at: http://circres.ahajournals.org/content/113/12/1275
Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document. Reprints: Information about reprints can be found online at: http://www.lww.com/reprints Subscriptions: Information about subscribing to Circulation Research is online at: http://circres.ahajournals.org//subscriptions/
Downloaded from http://circres.ahajournals.org/ at University of Exeter (exu) / England on March 18, 2015
D
espite numerous epidemiological studies demonstrating that high-density lipoprotein cholesterol (HDL-C) levels are inversely associated with cardiovascular risk,1–3 several lines of evidence now indicate that targeting HDL-C levels to reduce the risk of cardiovascular events is unlikely to be effective. Studies of pharmacological interventions to raise HDL-C, such as niacin4,5 and 2 cholesteryl ester transfer protein inhibitors,6,7 have shown no benefit in reducing cardiovascular events. In addition, data from a large Mendelian randomization study have shown that some genetic variants associated with HDL-C seem to have little relationship to coronary heart disease.8 As a result, there is currently skepticism about whether interventions specifically to raise HDL-C levels will decrease the risk of cardiovascular events.
Article, see p 1345 This failure of the so-called HDL cholesterol hypothesis has been accompanied by a shift toward a more rigorous, basic understanding of HDL as a molecule with multiple functions that can be differentiated from simple measures of HDL cholesterol mass. One of the important functions of HDL is its role in promoting cellular cholesterol efflux and reverse cholesterol transport. Our group and others have shown that the capacity of HDL to promote cholesterol efflux from macrophages ex vivo is inversely related to the risk of coronary heart disease even after controlling for HDL-C levels.9,10 Furthermore, niacin therapy does not augment cholesterol efflux despite raising HDL levels in statin-treated patients,11 which could explain the lack of efficacy of niacin despite increased HDL-C levels. Although more studies are certainly warranted, one hypothesis is that therapies that improve cholesterol efflux capacity and reverse cholesterol transport, such as infusion of a reconstituted HDL12 composed of apolipoprotein A1 and phospholipids, may improve cardiovascular outcomes. Beyond promoting cholesterol efflux, HDL is known to have anti-inflammatory,13 antioxidant,14 and nitric oxide (NO)–promoting functions.15 HDL particles have been shown to be dysfunctional in various disease states such as diabetes The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association. From the Division of Cardiology, Department of Medicine (A.J.) and Institute for Translational Medicine and Therapeutics, Cardiovascular Institute, and Department of Medicine (D.J.R.), University of Pennsylvania, Philadelphia. Correspondence to Daniel J. Rader, MD, 11th Floor, Smilow Center for Translational Research,3400 Civic Center Blvd, Bldg 421,Philadelphia, PA 19104-5158. E-mail [email protected] (Circ Res. 2013;113:1275-1277.) © 2013 American Heart Association, Inc. Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.113.302667
mellitus and psoriasis, with evidence of reduced protective functions of HDL potentially contributing to increased cardiovascular risk.16,17 In this issue of Circulation Research, Adams et al18 show that HDL is dysfunctional in congestive heart failure (CHF) specifically with respect to its ability to promote NO production from endothelial cells. They show that HDL from New York Heart Association Class II and III patients, compared with HDL from healthy subjects, has significantly reduced the ability to activate endothelial NO synthase (eNOS) and generate NO production. They suggest a mechanism linked to significantly reduced paraxonase-1 and increased HDL malondialdehyde, leading to increased stimulation of protein kinase C βII phosphorylation and altered phosphorylation of eNOS. Exercise training in subjects with CHF significantly improved the ability of HDL to promote NO biosynthesis. These studies extend previous work showing that HDL isolated from patients with coronary artery disease and acute coronary syndrome is defective in its ability to promote NO production.19 Although these findings are extremely provocative, this is a small, hypothesis-generating study with only 24 heart failure subjects and 16 healthy controls. It is surprising that although >80% of the controls were hypertensive, control subjects did not seem to benefit from exercise training to the same degree as patients with heart failure. Furthermore, although one might predict that patients with ischemic heart disease would be treated with statins compared with healthy controls, the low density lipoprotein (LDL) levels were not significantly lower between the heart failure subjects and controls at the beginning of the study. The authors do not comment on which patients in this study were treated with statins, which have been suggested to attenuate the proinflammatory effects of HDL.20 Finally, because heart failure often improves with medical therapy alone, the duration of time these patients were stable on optimal medical therapy is an important variable that could explain improvements seen in heart failure, independent of exercise training. The authors propose that the improvement in endothelial function after exercise training in patients with heart failure may be because of improvements in the quality of their HDL. To support this argument, the authors demonstrate a significant correlation between absolute change in endothelial function and HDL-induced NO production in patients with heart failure. A lack of improvement in endothelial function in the control group, which did not benefit from improved HDL function, would strengthen their argument. It is of course possible that exercise training improved both endothelial function and HDL function and that these 2 effects were independent. Could the improvements in LDL, which are known to negatively affect NO production,21 be responsible for the changes in endothelial function? Of note, LDL levels did decrease significantly with
Downloaded from http://circres.ahajournals.org/ at University of Exeter (exu) / England on March 18, 2015 1275
1276 Circulation Research December 6, 2013
Figure. Healthy high-density lipoprotein (HDL) and HDL containing sphingosine 1-phosphate (S1P) promote nitric oxide (NO) production through activation of scavenger receptor B1 (SR-BI) and S1PR3 receptor. Dysfunctional HDL rich in malondialdehyde (MDA) and symmetrical dimethylarginine (SDMA) decreases NO production via activation of lectin-like oxidized LDL receptor-1 (LOX-1) or Tolllike receptor-2 (TLR-2). eNOS indicates endothelial nitric oxide synthase; PI3K, phosphoinositide-3 kinase; and PKC-βII, protein kinase C βII.
exercise training. It is possible that in vivo, increased levels of lipid peroxidases seen by the authors correlate with higher levels of oxidized LDL that disrupt eNOS function.21 Exercise training itself is known to have positive effects on CHF, including reductions in all-cause mortality and heart failure hospitalization.22,23 What are the possible mechanisms by which exercise may benefit a patient with CHF? Possibilities include improvements in endothelial function, coronary perfusion, decreased peripheral vascular resistance, skeletal muscle remodeling, or increasing oxygen uptake and resistance to fatigue.24 In this study, a brief 12-week exercise training program improved peak oxygen consumption, one of the strongest predictors of mortality in CHF. If the benefit of exercise training in heart failure is significantly related to its ability to promote endothelial function, and HDL has the same effects, then improving HDL function in and of itself might be a reasonable target of therapy in heart failure. To understand whether HDL could be of therapeutic benefit in heart failure, a more detailed understanding of mechanism will be necessary. What are the molecular mechanisms that underlie the effects of exercise training on HDL-stimulated NO production in heart failure? The authors speculate that exercise training reduces overall oxidative load, as assayed by measuring plasma lipid peroxidases, causing a decrease in malondialdehyde binding to HDL. Because there was no effect of exercise training on paraxonase-1 activity or the HDL proteome, the authors eliminate these as possible molecular mechanisms. The authors discuss that HDL binding to scavenger receptor B1 may stimulate eNOS.25 One possibility is that malondialdehyde-rich HDL is less able to bind to scavenger receptor B1. Another intriguing, but unexplored, hypothesis is that changes in the HDL lipidome may be responsible for the enhanced NO production that occurs after exercise. The HDLassociated sphingolipid sphingosine 1-phosphate (S1P) binds
the S1P3 G-protein–coupled receptor to active phosphoinositide-3 kinase and Akt leading to eNOS activation.26 Animal models indicate that HDL/S1P may have numerous cardioprotective and vasculoprotective effects.27,28 However, in a mouse model of cardiomyopathy, S1P levels are actually increased because of downregulation of the cystic fibrosis transmembrane regulator, the major intracellular important mechanism for S1P.29 HDL-associated S1P may be decreased in patients with coronary artery disease,30 but changes in HDL/S1P levels have not been described in CHF or after chronic exercise training in humans. One may speculate that perhaps certain lipid-modified HDL, such as malondialdehyde-rich HDL, is not able to properly target S1P to its receptors on endothelial cells, resulting in decreased Akt activation and NO production. The authors leave unexplored the mechanisms by which dysfunctional HDL may stimulate protein kinase C βII, thereby inhibiting NO production. One possibility is that dysfunctional HDL signals through other receptors, such as lectin-like oxidized LDL receptor-1, to stimulate protein kinase C βII.19 Perhaps there are additional modifications of HDL in heart failure, such as increased symmetrical dimethylarginine, which are associated with further endothelial dysfunction via activation of Toll-like receptor-2.31 We propose a model whereby healthy HDL signals through scavenger receptor B1 and S1PR3 to induce NO production but speculate that dysfunctional HDL may cause decreased NO production via activation of lectin-like oxidized LDL receptor-1 or Toll-like receptor-2 (Figure). In summary, the findings of Adams et al18 further highlight that HDL function can be separated from HDL-C mass with regard to association with cardiovascular disease and relevant clinical end points. It remains tempting to speculate that interventions that improve HDL functional properties, such as cholesterol efflux capacity or NO promotion, would reduce
Downloaded from http://circres.ahajournals.org/ at University of Exeter (exu) / England on March 18, 2015
Javaheri and Rader Exercise Training Augments NO Production in CHF 1277 cardiovascular events. In fact, targeting NO in CHF patients with therapies such as hydralazine and nitrates provides cardiovascular outcome benefit in selected patients.32 Although it has not been tested in heart failure, reconstituted HDL is known to improve endothelial function in hypercholesterolemic men.33 In light of this report, it would be of substantial interest to determine whether reconstituted HDL can improve eNOS activity and NO production in patients with CHF. If so, it would then be appropriate to consider whether reconstituted HDL may improve outcomes in patients with CHF.
Disclosures Dr Rader receives personal consulting fees from Merck, Eli Lilly, and Vascular Strategies.
References 1. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15. 2. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988;8:737–741. 3. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis. 1988;8:207–211. 4. HPS2-THRIVE Collaborative Group. Hps2-thrive randomized placebocontrolled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279–1291 5. Boden WE, Probstfield JL, Anderson T, Chaitman BR, DesvignesNickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267 6. Schwartz GG, Olsson AG, Abt M, et al.; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099. 7. Barter PJ, Caulfield M, Eriksson M, et al.; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122. 8. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380:572–580. 9. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–135. 10. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, Hazen SL. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol. 2013;33:1696–1705. 11. Khera AV, Patel PJ, Reilly MP, Rader DJ. The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol. 2013;62:1909–1910. 12. Patel S, Drew BG, Nakhla S, Duffy SJ, Murphy AJ, Barter PJ, Rye KA, Chin-Dusting J, Hoang A, Sviridov D, Celermajer DS, Kingwell BA. Reconstituted high-density lipoprotein increases plasma highdensity lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol. 2009;53: 962–971. 13. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95:764–772. 14. Navab M, Yu R, Gharavi N, Huang W, Ezra N, Lotfizadeh A, Anantharamaiah GM, Alipour N, Van Lenten BJ, Reddy ST, Marelli D. High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr Atheroscler Rep. 2007;9:244–248.
15. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoproteininduced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 2003;278:9142–9149. 16. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol. 2010;30:151–155. 17. Mehta NN, Li R, Krishnamoorthy P, Yu Y, Farver W, Rodrigues A, Raper A, Wilcox M, Baer A, DerOhannesian S, Wolfe M, Reilly MP, Rader DJ, VanVoorhees A, Gelfand JM. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012;224:218–221. 18. Adams V, Besler C, Fischer T, et al. Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties. Circ Res. 2013;113:1345–1355. 19. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121:2693–2708. 20. Navab M, Anantharamaiah GM, Hama S, Hough G, Reddy ST, Frank JS, Garber DW, Handattu S, Fogelman AM. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2005;25:1426–1432. 21. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem. 1999;274:32512–32519. 22. O’Connor CM, Whellan DJ, Lee KL, et al.; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1439–1450. 23. Belardinelli R, Georgiou D, Cianci G, Purcaro A. 10-year exercise training in chronic heart failure: a randomized controlled trial. J Am Coll Cardiol. 2012;60:1521–1528. 24. Downing J, Balady GJ. The role of exercise training in heart failure. J Am Coll Cardiol. 2011;58:561–569. 25. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, Marcel YL, Anderson RG, Mendelsohn ME, Hobbs HH, Shaul PW. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001;7:853–857. 26. Nofer JR, van der Giet M, Tölle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004;113:569–581. 27. Theilmeier G, Schmidt C, Herrmann J, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation. 2006;114:1403–1409. 28. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of highdensity lipoprotein effects in cardiovascular protection. Cardiovasc Res. 2009;82:201–211. 29. Meissner A, Yang J, Kroetsch JT, Sauvé M, Dax H, Momen A, NoyanAshraf MH, Heximer S, Husain M, Lidington D, Bolz SS. Tumor necrosis factor-α-mediated downregulation of the cystic fibrosis transmembrane conductance regulator drives pathological sphingosine1-phosphate signaling in a mouse model of heart failure. Circulation. 2012;125:2739–2750. 30. Sattler KJ, Herrmann J, Yün S, Lehmann N, Wang Z, Heusch G, Sack S, Erbel R, Levkau B. High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention. Eur Heart J. 2009;30:1894–1902. 31. Speer T, Rohrer L, Blyszczuk P, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity. 2013;38:754–768. 32. Cole RT, Kalogeropoulos AP, Georgiopoulou VV, Gheorghiade M, Quyyumi A, Yancy C, Butler J. Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions. Circulation. 2011;123:2414–2422. 33. Spieker LE, Sudano I, Hürlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Lüscher TF, Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399–1402.
Downloaded from http://circres.ahajournals.org/ at University of Exeter (exu) / England on March 18, 2015
High-Density Lipoprotein: NO Failure in Heart Failure Ali Javaheri and Daniel J. Rader Circ Res. 2013;113:1275-1277 doi: 10.1161/CIRCRESAHA.113.302667 Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Copyright © 2013 American Heart Association, Inc. All rights reserved. Print ISSN: 0009-7330. Online ISSN: 1524-4571
The online version of this article, along with updated information and services, is located on the World Wide Web at: http://circres.ahajournals.org/content/113/12/1275
Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document. Reprints: Information about reprints can be found online at: http://www.lww.com/reprints Subscriptions: Information about subscribing to Circulation Research is online at: http://circres.ahajournals.org//subscriptions/
Downloaded from http://circres.ahajournals.org/ at University of Exeter (exu) / England on March 18, 2015
![[Perioperative heart failure - acute intraoperative heart failure].](/assets/img/hold.png)
